• Grzegorz Charliński, Agata Tyczyńska, Bartosz Małecki, Szymon Fornagiel, Agnieszka Barchnicka, Agnieszka Kołkowska, Anna Kopińska, Lidia Usnarska-Zubkiewicz, Paweł Robak, Anna Waszczuk-Gajda, Mateusz Krzystański, and Artur Jurczyszyn.
• Department of Hematology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration’s Hospital, Olsztyn, Poland
• Pol. Arch. Med. Wewn. 2021 Jun 29; 131 (6): 527-534.

AbstractINTRODUCTION Despite the progress made in the treatment of multiple myeloma (MM), approximately 10% to 15% of patients die within the first year of diagnosis. OBJECTIVES The aim of the study was to determine risk factors of early mortality in patients with newly diagnosed MM treated with new drugs in clinical practice. PATIENTS AND METHODS This multicenter analysis included 197 patients with symptomatic MM, diagnosed between October 2006 and November 2019, with a survival of less than 12 months. RESULTS The median overall survival was 2.5 months. The most common causes of early mortality were infections (35%), MM progression (23.8%), and cardiovascular disease (14.2%). In a multivariable analysis, the Zubrod performance score (P = 0.02), history of cardiovascular disease (P = 0.04), dependence on renal dialysis (P = 0.03), and MM response (P <0.001) were associated with early mortality. CONCLUSIONS Early mortality in MM patients requires further studies. When qualifying patients with newly diagnosed MM for chemotherapy, it is necessary to consider performance status and the history of comorbidities, including cardiovascular diseases.

6 keywords...

hide…